Healthcare Wrap Week 12: Racura rockets on trial green light as Imugene tumbles on $20m raise

Racura Oncology (ASX:RAC) led the board with 30.41% after it won governance approval to launch its Phase 1 HARNESS-1 study, pairing RC220 with osimertinib in EGFR-mutated lung cancer. Imugene (ASX:IMU) was the big faller, down -18.92% after launching a $20 million capital raise to push its azer-cel program. Neurotech International (ASX:NTI) also dropped hard, down -16.67%, even though it activated the first Phase 3 trial site for its autism treatment NTI164.

Cancer trials: “permission to start” still moves stocks

Racura’s jump was a simple trade: investors like it when a trial moves from planning to starting. Governance approval means the study can begin activating sites and screening patients. In plain terms, it reduces the chance the plan gets stuck in paperwork. Percheron Therapeutics (ASX:PER) went the other way, down -16.67% after announcing a $2.2 million entitlement offer at a discount. Discounted raises often pull the share price down because new shares are being sold cheaper. Percheron also reopened lower and then kept falling during the session, which showed selling pressure didn’t clear quickly. Imugene’s sell-off followed the same logic, but on a bigger scale. A $20 million raising can be the right move for a clinical program, but it increases the number of shares on issue. That can reduce what each existing share represents unless the program’s value rises faster than the dilution.

Imaging and diagnostics: strong data helps, but timing matters

Telix Pharmaceuticals (ASX:TLX) rose 12.93% after resubmitting its FDA application for Pixclara, a PET scan agent for glioma imaging. Investors cared because a resubmission means Telix has answered the FDA’s earlier questions with more data and analysis. It brings the product closer to a yes-or-no decision. Clarity Pharmaceuticals (ASX:CU6) fell -10.70% despite eye-catching Phase II results for its Cu-SAR-bisPSMA scan in prostate cancer recurrence. The study reported more lesion detection than the current standard and a change in patient management. The price drop suggests some holders took profits or worried about what comes next: Phase III completion and the time and cost of regulatory submission. BlinkLab (ASX:BB1) slipped -3.49% after finalising its 10-site US network for a pivotal FDA 510(k) trial of its autism diagnostic aid. The update was operational rather than financial. Patient testing is expected to start late March 2026, so there’s still a wait before new accuracy results land.

Regulators and US expansion: progress, but investors want proof of sales

EBR Systems (ASX:EBR) eased -4.05% even after a major step: FDA approval of its WiSE CRT System and the start of US commercial implants, producing $1.6 million revenue in 2025. The sticking point was the scale of losses and spending. A net loss of $48.8 million and a large capital raise tell investors more cash will be used before the business becomes self-funding. CLINUVEL Pharmaceuticals (ASX:CUV) fell -2.92% despite record first-half profits and A$233 million cash. The company confirmed CEO Philippe Wolgen stays on for another 24, 36 months and said vitiligo is now the priority. It also flagged plans to upgrade its US depositary receipt program and pursue a Nasdaq listing in H1 2026. For now, some investors may be waiting for clearer timing on the vitiligo clinical program and what a US listing changes day to day. Imricor Medical Systems (ASX:IMR) dipped -2.26% after filing a Form 10 with the US SEC. In plain English, that’s a step into fuller US reporting rules, often used by companies preparing for broader US investor access. It doesn’t change sales next week, so the share price reaction was muted.

Funding and cash updates: the market rewarded “non-dilutive” money

Several companies topped up cash without selling new shares. EMVision (ASX:EMV) gained an extra funding buffer via a $3.8 million R&D tax rebate, and Argenica (ASX:AGN) received $3.97 million with pro-forma cash of $9 million at 31 December 2025. Resonance Health (ASX:RHT) also banked a $732,851 refund. These payments matter because they pay bills without increasing share count. Not all funding news landed well. Cann Group (ASX:CAN) fell -14.29% after a $750,000 convertible note, which can later turn into shares. If conversion happens at a low price, existing holders can end up owning a smaller slice. Tetratherix (ASX:TTX) jumped 15.87% after launching a precision medicine franchise and signing a 10-year exclusive deal with Superpower Health, including a US$3 million annual licence fee. The stock reopened higher and then kept rising, suggesting buyers believed the revenue is real and near term.

Medicinal cannabis: distribution wins, but balance sheet choices still bite

Vitura Health (ASX:VIT) fell -5.00% despite a binding distribution agreement with MedReleaf Australia, with a stated potential to add up to $15 million a year. The catch is spelled out: there are no minimum purchase commitments. Sales depend on doctors, patients, and pricing in a competitive market. Little Green Pharma (ASX:LGP) dropped -12.38% after walking away from a sale-and-leaseback plan for its WA facility due to unattractive terms. Management said operations won’t change, but investors often read this as “cash from the deal isn’t coming”, which can bring funding worries forward. Neurizon Therapeutics (ASX:NUZ) also sold off, down -12.50%, after its CEO resigned and the chair stepped in as interim leader while a global search begins. A leadership change can scare investors because it introduces delays and uncertainty, even if the pipeline is unchanged.